Biopharmacologic Properties of Resveratrol

Document Type : Review Article

Authors

1 Department of Anatomical Sciences, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Assistant Professor, Department of Internal Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

3 Professor, Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Abstract

Background: Resveratrol is a polyphenolic phytoalxine agent which is found in grapes, berries and peanuts. It is one of the important biomolecules with different biopharmacologic properties in modern medicine. To date, many experimental and animal researches were done on its properties and functions; the aim of present study was to introduce different properties of this important biomolecule.Methods: Acceptable database, Scopus, Pubmed and ISI, were searched with keyword of resveratrol. After the primary survey of the title by research team, and determination of common articles, abstracts of selected article were chosen and finally near to one hundred articles were included in the study. Important data were summarized and rewrite by research team, and were categorized and presented here.Findings: Resveratrol had antioxidant activities and was used in treatment of cardiovascular diseases, obesity and diabetes. In addition, it prevented gastric, lung, breast, and prostate, liver and colorectal cancer developments. Resveratrol showed anti-inflammatory, anti-aging and anti-Alzheimer's disease effects, and worked as regulator of cell cycle and programmed cell death (apoptosis). Resveratrol had strong estrogenic-like effects.Conclusion: Resveratrol is an important biomolecule with different medical properties which many studies were done on its new application and it get pivotal position in this area.

Keywords

References

  1. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009; 486(2): 95-102.
  2. Dercks W, Creasy LL. Influence of fosetyl-Al on phytoalexin accumulation in the Plasmopara viticola-grapevine interaction. Physiological and Molecular Plant Pathology 1989; 34(3): 203-13.
  3. Chen X, He H, Wang G, Yang B, Ren W, Ma L, et al. Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. Biomed Chromatogr 2007; 21(3): 257-65.
  4. Trela BC, Waterhouse AL. Resveratrol:Isomeric molar absorptivities and stability. J Agric Food Chem 1996; 44(5): 1253-7.
  5. Sobolev VS, Cole RJ. Trans-resveratrol content in commercial peanuts and peanut products. J Agric Food Chem 1999; 47(4): 1435-9.
  6. Vian MA, Tomao V, Gallet S, Coulomb PO, Lacombe JM. Simple and rapid method for cis- and trans-resveratrol and piceid isomers determination in wine by high-performance liquid chromatography using chromolith columns. J Chromatogr A 2005; 1085(2): 224-9.
  7. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. J Chem Soc Japan 1939: 60(11): 1090-100.
  8. Mishra RN. Resveratrol-the new rasayan (anti aging) drug. Current Research in Medicine and Medical Sciences 2011; 1(1): 5-18.
  9. Hillis WE, Hart JH, Yazaki Y. Polyphenols of Eucalyptus sideroxylon wood. Phytochemistry 1974: 13 (8): 1591-5.
  10. King RE, Bomser JA, Min DB. Bioactivity of resveratrol. Comprehensive Reviews in Food Science and Food Safety 2006; 5(3): 65-70.
  11. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 2002; 50(3): 431-5.
  12. Soleas GJ, Yan J, Goldberg DM. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 2001; 757(1): 161-72.
  13. Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32(12): 1377-82.
  14. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33(3): 387-98.
  15. Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49(5): 482-94.
  16. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003; 72(20): 2219-33.
  17. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215: 9-15.
  18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5): 705-16.
  19. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273(34): 21875-82.
  20. Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res 2005; 11(5): 1918-27.
  21. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, Munoz E, et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 2007; 4: 25.
  22. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224(3): 274-83.
  23. Afaq F, Adhami VM, Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol 2003; 186(1): 28-37.
  24. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
  25. Reagan-Shaw S, Afaq F, Aziz MH, Ahmad N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene 2004; 23(30): 5151-60.
  26. Le CL, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 2005; 49(5): 462-71.
  27. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000; 66(9): 769-77.
  28. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997; 94(25): 14138-43.
  29. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 291(4): 1001-5.
  30. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006; 231(1): 113-22.
  31. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 2008; 66(8): 445-54.
  32. Mahady GB, Pendland SL. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol 2000; 95(7): 1849.
  33. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol 2006; 12(35): 5628-34.
  34. Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 2013; 57(7): 1170-81.
  35. Khazaei S, Khazaei M, Kazemi S, Yaghini J. Resveratrol as a supplemental treatment for periodontitis. Dent Res J (Isfahan) 2012; 9(5): 655-7.
  36. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95(9): E1-E8.
  37. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della RF. Resveratrol: from basic science to the clinic. Cell Cycle 2007; 6(20): 2495-510.
  38. King RE, Kent KD, Bomser JA. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact 2005; 151(2): 143-9.
  39. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011; 1215: 22-33.
  40. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993; 341(8852): 1103-4.
  41. Holthoff JH, Woodling KA, Doerge DR, Burns ST, Hinson JA, Mayeux PR. Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochem Pharmacol 2010; 80(8): 1260-5.
  42. Dobrydneva Y, Williams RL, Blackmore PF. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br J Pharmacol 1999; 128(1): 149-57.
  43. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444(7117): 337-42.
  44. Shang J, Chen LL, Xiao FX. Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Zhonghua Gan Zang Bing Za Zhi 2008; 16(8): 616-9.
  45. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635(1-3): 1-8.
  46. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127(6): 1109-22.
  47. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009; 58(2): 344-51.
  48. Hong HJ, Kang W, Kim DG, Lee DH, Lee Y, Han CH. Effects of resveratrol on the insulin signaling pathway of obese mice. J Vet Sci 2014; 15(2): 179-85.
  49. Bagchi D, Das DK, Tosaki A, Bagchi M, Kothari SC. Benefits of resveratrol in women's health. Drugs Exp Clin Res 2001; 27(5-6): 233-48.
  50. Singh M, Parent S, Leblanc V, Asselin E. Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner. Biol Reprod 2011; 84(5): 1045-52.
  51. Maia H, Jr., Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health 2012; 4: 543-9.
  52. Hsia SM, Wang KL, Wang PS. Effects of resveratrol, a grape polyphenol, on uterine contraction and Ca(2)+ mobilization in rats in vivo and in vitro. Endocrinology 2011; 152(5): 2090-9.
  53. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54(2): 111-8.
  54. Anekonda TS. Resveratrol--a boon for treating Alzheimer's disease? Brain Res Rev 2006; 52(2): 316-26.
  55. Camins A, Junyent F, Verdaguer E, Beas-Zarate C, Rojas-Mayorquin AE, Ortuno-Sahagun D, et al. Resveratrol: an antiaging drug with potential therapeutic applications in treating diseases. Pharmaceuticals (Basel) 2009; 2(3): 194–205.
  56. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430(7000): 686-9.
  57. West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Dev Neurosci. 2007; 29(4-5): 363-72.
  58. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425(6954): 191-6.
  59. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16(3): 296-300.
  60. Tyagi S, Sharma A., Aggarwal G. Clinical and medicinal application of resveraterol: a reviwe. International Journal of Pharmaceutical Sciences Review and Research 2010; 3(1): 49-52.
  61. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 2006; 13(1): 87-98.
  62. Sathis Kumar D, Shankar P, Upender Rao G. Health benefits of resveratrol. International Journal of Pharmaceutical Sciences and Nanotechnology 2009: 2 (1): 327-32.
  63. Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers DR, et al. Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 2006; 15(7): 538-46.
  64. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8(3): 893-903.
  65. Liang YC, Tsai SH, Chen L, Lin-Shiau SY, Lin JK. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol 2003; 65(7): 1053-60.
  66. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004; 91(1): 178-85.
  67. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92(3): 996-1002.
  68. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003; 278(42): 41482-90.
  69. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 2000; 130(5): 1115-23.
  70. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002; 23(3): 425-34.
  71. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 2007; 13(17): 5162-9.
  72. Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol 2005; 56(Suppl 1): 51-67.
  73. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294(3): L478-L488.
  74. Chen JC, Chen Y, Lin JH, Wu JM, Tseng SH. Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res 2006; 26(2A): 1237-45.
  75. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15(10): 1798-800.
  76. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003; 64(5): 1029-36.
  77. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci 2004; 82(2): 614-9.
  78. Borriello A, Cucciolla V, Della RF, Galletti P. Dietary polyphenols: focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr Metab Cardiovasc Dis 2010; 20(8): 618-25.
  79. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010; 54(1): 7-16.
  80. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2014; 12(12): 2092-103.
  81. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49(7): 449-54.
  82. Kwak SS, Cheong SA, Jeon Y, Lee E, Choi KC, Jeung EB, et al. The effects of resveratrol on porcine oocyte in vitro maturation and subsequent embryonic development after parthenogenetic activation and in vitro fertilization. Theriogenology 2012; 78(1): 86-101.
  83. Lee K, Wang C, Chaille JM, Machaty Z. Effect of resveratrol on the development of porcine embryos produced in vitro. J Reprod Dev 2010; 56(3): 330-5.
  84. Wang F, Tian X, Zhang L, He C, Ji P, Li Y, et al. Beneficial effect of resveratrol on bovine oocyte maturation and subsequent embryonic development after in vitro fertilization. Fertil Steril 2014; 101(2): 577-86.
  85. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148(3): 421-33.
  86. Kwak SS, Hyun SH. The effects of resveratrol on oocyte maturation and preimplantation embryo development. J Emb Trans 2012; 27(2): 71-80.
Journal of Isfahan Medical School
Volume 32, Issue 308 - Serial Number 308
September and October 2015
Pages 1879-1896

Files

History

  • Receive Date: 17 July 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics